Trial Profile

A confirmatory Phase III trial of Lanifibranor in patients with NASH and compensated cirrhosis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lanifibranor (Primary)
Indications Liver cirrhosis; Non-alcoholic steatohepatitis
Focus Registrational; Therapeutic Use
Sponsors Inventiva Pharma

Most Recent Events

06 Jan 2023 Planned number of patients changed to 800.
06 Jan 2023 New trial record
04 Jan 2023 According to an Inventiva Pharma media release, if results of this trial successful, are expected to support the submission for FDA full approval and expand the addressable patient population beyond patients with F2 and F3 fibrosis to include patients with NASH and compensated cirrhosis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com